Teva partners with Samsung Bioepis to commercialize two biosimilars in U.S

Bitget2026/11/03 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Teva entered a licensing and commercialization agreement with Samsung Bioepis for U.S. rights to two FDA-approved immunology biosimilars.
ETICOVO rights transfer at closing, expected by year-end 2026; infliximab-abda rights transfer in the third quarter of 2027.
Samsung Bioepis retains responsibility for regulatory oversight and manufacturing of both products.
Payments include an upfront payment over three years, potential launch and sales milestones, and shared commercialization profits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030500PRIMZONEFULLFEED1001301465) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Teva partners with Samsung Bioepis to commercialize two biosimilars in U.S

You may also like

Crypto prices